Braveheart Bio, Inc.
BRVEHealthcare|Biotechnology|US
$18.60
+1.19 (+6.80%)
Clinical Trials (1)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07755904 BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy | Cardiomyopathy, Hypertrophic Obstructive | P3 | Recruiting | 210 | RCT, Double-blind | BHB-1893, Metoprolol |